‘Merck Covid antiviral pill did not cut hospitalisation risk, study finds’ -Financial Times
https://www.ft.com/content/c3fe4791-72fb-4d01-ac59-707b39baa0b6
Verve’s Stock Price Could Continue To Rise Through Clinical Progress – Despite Worries About “DeeperPocketed” Competition
Credit Suisse has initiated coverage on Verve Therapeutics Inc (NASDAQ:VERV) with a Neutral rating and a $48 target price. Its lead assets…
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
Stephens initiated coverage on Myriad Genetics Inc (NASDAQ:MYGN) with an Equal-Weight rating and a price target of $22. The analyst writes that…
Stephen Initiates This Spatial Biology Player Citing Strong Competitive Position
Stephens started coverage on Akoya Biosciences Inc (NASDAQ:AKYA) with an Overweight rating and price target of $16. The analyst views Akoya…
This Analyst Cuts Integer’s Price Target Citing Choppy Macro Environment
Integer Holdings Corp (NYSE:ITGR) said Q3 sales were negatively impacted by approximately $15 million, primarily due to deteriorating delivery performance and…
Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction
Cyclerion Therapeutics Inc (NASDAQ:CYCN) is reprioritizing development programs and focusing resources and capabilities on candidates for mitochondrial diseases. The company has…
Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate
Surrozen Inc (NASDAQ:SRZN) entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for retinal diseases. SZN-413 is…
Aldeyra’s ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Aldeyra Therapeutics Inc (NASDAQ:ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection,…
CytoSorbents Secures US Govt Contract For Customized Filter Freeze-Dried Universal Plasma
The U.S. Army Medical Research Acquisition Activity has awarded CytoSorbents Corp (NASDAQ:CTSO) a three-year Phase 3 contract valued at $4.3 million for…
Eli Lilly’s Obesity Drug, Tirzepatide, Fast Tracked In US; Rolling Submission To Start This Year
The FDA has granted Fast Track designation for Eli Lilly And Co’s (NYSE: LLY) tirzepatide for adults with obesity or overweight with weight-related…